Intratumoral NKT cell accumulation promotes antitumor immunity in pancreatic cancer

Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2403917121. doi: 10.1073/pnas.2403917121. Epub 2024 Jul 9.

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a potentially lethal disease lacking effective treatments. Its immunosuppressive tumor microenvironment (TME) allows it to evade host immunosurveillance and limits response to immunotherapy. Here, using the mouse KRT19-deficient (sgKRT19-edited) PDA model, we find that intratumoral accumulation of natural killer T (NKT) cells is required to establish an immunologically active TME. Mechanistically, intratumoral NKT cells facilitate type I interferon (IFN) production to initiate an antitumor adaptive immune response, and orchestrate the intratumoral infiltration of T cells, dendritic cells, natural killer cells, and myeloid-derived suppressor cells. At the molecular level, NKT cells promote the production of type I IFN through the interaction of their CD40L with CD40 on myeloid cells. To evaluate the therapeutic potential of these observations, we find that administration of folinic acid to mice bearing PDA increases NKT cells in the TME and improves their response to anti-PD-1 antibody treatment. In conclusion, NKT cells have an essential role in the immune response to mouse PDA and are potential targets for immunotherapy.

Keywords: CD40–CD40L interaction; NKT cells; folinic acid; tumor microenvironment; type I IFN.

MeSH terms

  • Animals
  • Carcinoma, Pancreatic Ductal* / immunology
  • Carcinoma, Pancreatic Ductal* / pathology
  • Carcinoma, Pancreatic Ductal* / therapy
  • Humans
  • Immunotherapy / methods
  • Interferon Type I / immunology
  • Interferon Type I / metabolism
  • Leucovorin / administration & dosage
  • Leucovorin / therapeutic use
  • Mice
  • Mice, Inbred C57BL
  • Myeloid-Derived Suppressor Cells / immunology
  • Natural Killer T-Cells* / immunology
  • Pancreatic Neoplasms* / immunology
  • Pancreatic Neoplasms* / pathology
  • Pancreatic Neoplasms* / therapy
  • Tumor Microenvironment* / immunology

Substances

  • Interferon Type I
  • Leucovorin